1.51
0.12 (8.24%)
| 前收盘价格 | 1.40 |
| 收盘价格 | 1.39 |
| 成交量 | 1,524,300 |
| 平均成交量 (3个月) | 3,517,653 |
| 市值 | 126,406,472 |
| 价格/销量 (P/S) | 3.48 |
| 股市价格/股市净资产 (P/B) | 2.03 |
| 52周波幅 | |
| 利润日期 | 5 Aug 2025 - 11 Aug 2025 |
| 营业利益率 (TTM) | -758.05% |
| 稀释每股收益 (EPS TTM) | -3.04 |
| 季度收入增长率 (YOY) | 310.40% |
| 总债务/股东权益 (D/E MRQ) | 49.88% |
| 流动比率 (MRQ) | 3.08 |
| 营业现金流 (OCF TTM) | -208.21 M |
| 杠杆自由现金流 (LFCF TTM) | -103.52 M |
| 资产报酬率 (ROA TTM) | -36.80% |
| 股东权益报酬率 (ROE TTM) | -140.82% |
市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 看跌 | 看跌 |
| Biotechnology (全球的) | 看跌 | 看跌 | |
| 股票 | Editas Medicine, Inc. | 看跌 | 看跌 |
AIStockmoo 评分
| 分析师共识 | 1.0 |
| 内部交易活动 | NA |
| 价格波动 | -2.0 |
| 技术平均移动指标 | 0.0 |
| 技术振荡指标 | 0.5 |
| 平均 | -0.13 |
|
Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR)/ CRISPR-associated protein 9 (Cas9 technology). It has developed CRISPR/Cas9 technology which uses a protein-RNA (ribonucleic acid) complex composed of the Cas9 enzyme bound to a guide RNA molecule designed to recognize a DNA (deoxyribonucleic acid) sequence that requires repair. The company is engaged in developing and commercializing genome editing technology. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 投资方式 | Small Core |
| 内部持股比例 | 0.35% |
| 机构持股比例 | 54.01% |
| 52周波幅 | ||
| 目标价格波幅 | ||
| 高 | 4.00 (Baird, 164.90%) | 购买 |
| 中 | 3.50 (131.79%) | |
| 低 | 3.00 (HC Wainwright & Co., 98.68%) | 购买 |
| 平均值 | 3.50 (131.79%) | |
| 总计 | 2 购买 | |
| 平均价格@调整类型 | 1.54 | |
| 公司 | 日期 | 目标价格 | 调整类型 | 价格@调整类型 |
|---|---|---|---|---|
| Baird | 13 May 2025 | 4.00 (164.90%) | 购买 | 1.50 |
| HC Wainwright & Co. | 28 Apr 2025 | 3.00 (98.68%) | 购买 | 1.58 |
该时间范围内无数据。
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合